Literature DB >> 22290434

Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.

Irina Berlin1, Laurence Denat, Anne-Lise Steunou, Isabel Puig, Delphine Champeval, Sophie Colombo, Karen Roberts, Elise Bonvin, Yveline Bourgeois, Irwin Davidson, Véronique Delmas, Laurence Nieto, Colin R Goding, Lionel Larue.   

Abstract

MITF-M and PAX3 are proteins central to the establishment and transformation of the melanocyte lineage. They control various cellular mechanisms, including migration and proliferation. BRN2 is a POU domain transcription factor expressed in melanoma cell lines and is involved in proliferation and invasion, at least in part by regulating the expression of MITF-M and PAX3. The T361 and S362 residues of BRN2, both in the POU domain, are conserved throughout the POU protein family and are targets for phosphorylation, but their roles in vivo remain unknown. To examine the role of this phosphorylation, we generated mutant BRN2 in which these two residues were replaced with alanines (BRN2TS→BRN2AA). When expressed in melanocytes in vitro or in the melanocyte lineage in transgenic mice, BRN2TS induced proliferation and repressed migration, whereas BRN2AA repressed both proliferation and migration. BRN2TS and BRN2AA bound and repressed the MITF-M promoter, whereas PAX3 transcription was induced by BRN2TS but repressed by BRN2AA. Expression of the BRN2AA transgene in a Mitf heterozygous background and in a Pax3 mutant background enhanced the coat color phenotype. Our findings show that melanocyte migration and proliferation are controlled both through the regulation of PAX3 by nonphosphorylated BRN2 and through the regulation of MITF-M by the overall BRN2 level.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290434      PMCID: PMC3302439          DOI: 10.1128/MCB.06257-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

1.  PAX3 is expressed in human melanomas and contributes to tumor cell survival.

Authors:  F A Scholl; J Kamarashev; O V Murmann; R Geertsen; R Dummer; B W Schäfer
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

2.  The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells.

Authors:  K Lefort; J P Rouault; L Tondereau; J P Magaud; J F Doré
Journal:  Oncogene       Date:  2001-11-01       Impact factor: 9.867

3.  Differential dimer activities of the transcription factor Oct-1 by DNA-induced interface swapping.

Authors:  A Reményi; A Tomilin; E Pohl; K Lins; A Philippsen; R Reinbold; H R Schöler; M Wilmanns
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

4.  Tyrosine levels regulate the melanogenic response to alpha-melanocyte-stimulating hormone in human melanocytes: implications for pigmentation and proliferation.

Authors:  D J Schwahn; W Xu; A B Herrin; E S Bales; E E Medrano
Journal:  Pigment Cell Res       Date:  2001-02

5.  General strategy to analyse melanoma in mice.

Authors:  Stuart J Gallagher; Flavie Luciani; Irina Berlin; Florian Rambow; Gwendoline Gros; Delphine Champeval; Véronique Delmas; Lionel Larue
Journal:  Pigment Cell Melanoma Res       Date:  2011-09-29       Impact factor: 4.693

6.  Transcriptomic analysis of mouse embryonic skin cells reveals previously unreported genes expressed in melanoblasts.

Authors:  Sophie Colombo; Delphine Champeval; Florian Rambow; Lionel Larue
Journal:  J Invest Dermatol       Date:  2011-08-18       Impact factor: 8.551

7.  Structural characterization of the PIT-1/ETS-1 interaction: PIT-1 phosphorylation regulates PIT-1/ETS-1 binding.

Authors:  Kevin D Augustijn; Dawn L Duval; Rainer Wechselberger; Rob Kaptein; Arthur Gutierrez-Hartmann; Peter C van der Vliet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

8.  Cre-mediated recombination in the skin melanocyte lineage.

Authors:  Véronique Delmas; Silvia Martinozzi; Yveline Bourgeois; Martin Holzenberger; Lionel Larue
Journal:  Genesis       Date:  2003-06       Impact factor: 2.487

9.  The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.

Authors:  Frédéric Relaix; Mariarosa Polimeni; Didier Rocancourt; Carola Ponzetto; Beat W Schäfer; Margaret Buckingham
Journal:  Genes Dev       Date:  2003-12-01       Impact factor: 11.361

10.  The melanocortin 1 receptor is the principal mediator of the effects of agouti signaling protein on mammalian melanocytes.

Authors:  Z A Abdel-Malek; M C Scott; M Furumura; M L Lamoreux; M Ollmann; G S Barsh; V J Hearing
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

View more
  10 in total

1.  In silico studies of the interaction between BRN2 protein and MORE DNA.

Authors:  Ivan Evangelista do Vale Coelho; Denise Costa Arruda; Alex Gutterres Taranto
Journal:  J Mol Model       Date:  2016-08-27       Impact factor: 1.810

Review 2.  Octamer-binding transcription factors: genomics and functions.

Authors:  Feng-Qi Zhao
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 3.  MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma.

Authors:  Michael R Eccles; Shujie He; Antonio Ahn; Lynn J Slobbe; Aaron R Jeffs; Han-Seung Yoon; Bruce C Baguley
Journal:  Front Oncol       Date:  2013-09-11       Impact factor: 6.244

4.  Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells.

Authors:  Danielle Bartlett; Glen M Boyle; Mel Ziman; Sandra Medic
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

Review 5.  In the Wnt-er of life: Wnt signalling in melanoma and ageing.

Authors:  Amanpreet Kaur; Marie R Webster; Ashani T Weeraratna
Journal:  Br J Cancer       Date:  2016-10-20       Impact factor: 7.640

6.  CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations.

Authors:  Hironobu Okuno; Francois Renault Mihara; Shigeki Ohta; Kimiko Fukuda; Kenji Kurosawa; Wado Akamatsu; Tsukasa Sanosaka; Jun Kohyama; Kanehiro Hayashi; Kazunori Nakajima; Takao Takahashi; Joanna Wysocka; Kenjiro Kosaki; Hideyuki Okano
Journal:  Elife       Date:  2017-11-28       Impact factor: 8.140

7.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

8.  Profiling and metaanalysis of epidermal keratinocytes responses to epidermal growth factor.

Authors:  Miroslav Blumenberg
Journal:  BMC Genomics       Date:  2013-02-08       Impact factor: 3.969

9.  A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.

Authors:  Alejandro Conde-Perez; Gwendoline Gros; Christine Longvert; Malin Pedersen; Valérie Petit; Zackie Aktary; Amaya Viros; Franck Gesbert; Véronique Delmas; Florian Rambow; Boris C Bastian; Andrew D Campbell; Sophie Colombo; Isabel Puig; Alfonso Bellacosa; Owen Sansom; Richard Marais; Leon C L T Van Kempen; Lionel Larue
Journal:  Nat Commun       Date:  2015-08-26       Impact factor: 14.919

10.  Prenatal diagnosis and genetic counseling for Waardenburg syndrome type I and II in Chinese families.

Authors:  Li Wang; Litao Qin; Tao Li; Hongjian Liu; Lingcao Ma; Wan Li; Dong Wu; Hongdan Wang; Qiannan Guo; Liangjie Guo; Shixiu Liao
Journal:  Mol Med Rep       Date:  2017-10-25       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.